We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Read MoreHide Full Article
Key Takeaways
Stryker's Q2 sales rose 9.4%, while adjusted EPS climbed 17.9% and operating margin improved.
SYK narrowed 2026 organic sales growth guidance to 8.3%-9.3% and adjusted EPS to $14.95-$15.10.
Stryker must convert elevated backlog while managing cyber costs and Peripheral Vascular supply issues.
Stryker Corporation (SYK - Free Report) entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook.
The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management’s expectations materializes.
Stryker’s Q2 Recovery Rebuilt Momentum
Stryker reported second-quarter net sales of $6.6 billion, up 9.4% year over year. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share.
Profitability improved with the recovery. Adjusted operating margin reached 27.4%, up 170 basis points year over year, as stronger sales, improved gross margin and spending discipline helped offset lingering operating pressures. MedSurg and Neurotechnology grew 9.2% organically, while Orthopaedics advanced 8.6%, showing that the rebound extended across both major businesses.
SYK’s Guidance Sets a High Bar for the Second Half
Management narrowed its 2026 organic sales growth outlook to 8.3%-9.3% and adjusted earnings guidance to $14.95-$15.10 per share. The ranges assume continued recovery execution after the first-quarter disruption rather than a simple continuation of second-quarter catch-up.
The sales outlook includes a modestly positive pricing contribution. Foreign exchange is also expected to have a slightly favorable effect on sales and adjusted earnings if rates remain near current levels. Meeting the guidance therefore depends heavily on operational delivery through the rest of the year.
Capital demand provides visibility into that second-half opportunity. Stryker exited the quarter with elevated backlog and strong orders, while management expects continued production ramping to support higher deliveries. Mako recorded its best-ever second quarter for installations in both the United States and international markets.
The core question is capacity. Management said the company has the orders to support high growth but must manufacture enough capital equipment to convert demand into reported sales. The competitive robotics backdrop remains active. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) recently received U.S. clearance and completed first cases with its next-generation ROSA Shoulder System. Intuitive Surgical, Inc. (ISRG - Free Report) is also expanding placements of its da Vinci 5 platform, reinforcing continued hospital interest in robotic-assisted surgery.
SYK Still Carries Cyber and Supply Risks
The recovery still carries costs. Cyber remediation and stabilization spending is expected to continue in the second half, while manufacturing and supply-chain pressures remain part of the margin picture. Those expenses can limit operating leverage even as production normalizes.
Peripheral Vascular is another execution point. A supply disruption created a meaningful U.S. back-order position and lost sales in the second quarter. Management expects those back orders to reach a manageable level by the end of the third quarter, but any slower improvement could affect the cadence of the broader recovery.
Stryker’s Ranking Signals Are Not Provided
The second-half setup is stronger, but it is not automatic. Backlog, capital demand and product activity support the growth case, while production constraints, vascular supply issues and cyber-related costs keep the risk-reward balance measured.
Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The near-term case rests on whether Stryker converts demand into sales while protecting the margin recovery. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Key Takeaways
Stryker Corporation (SYK - Free Report) entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook.
The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management’s expectations materializes.
Stryker’s Q2 Recovery Rebuilt Momentum
Stryker reported second-quarter net sales of $6.6 billion, up 9.4% year over year. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share.
Profitability improved with the recovery. Adjusted operating margin reached 27.4%, up 170 basis points year over year, as stronger sales, improved gross margin and spending discipline helped offset lingering operating pressures. MedSurg and Neurotechnology grew 9.2% organically, while Orthopaedics advanced 8.6%, showing that the rebound extended across both major businesses.
SYK’s Guidance Sets a High Bar for the Second Half
Management narrowed its 2026 organic sales growth outlook to 8.3%-9.3% and adjusted earnings guidance to $14.95-$15.10 per share. The ranges assume continued recovery execution after the first-quarter disruption rather than a simple continuation of second-quarter catch-up.
The sales outlook includes a modestly positive pricing contribution. Foreign exchange is also expected to have a slightly favorable effect on sales and adjusted earnings if rates remain near current levels. Meeting the guidance therefore depends heavily on operational delivery through the rest of the year.
Stryker Corporation Revenue (Quarterly)
Stryker Corporation revenue-quarterly | Stryker Corporation Quote
Stryker’s Backlog Can Convert Into Growth
Capital demand provides visibility into that second-half opportunity. Stryker exited the quarter with elevated backlog and strong orders, while management expects continued production ramping to support higher deliveries. Mako recorded its best-ever second quarter for installations in both the United States and international markets.
The core question is capacity. Management said the company has the orders to support high growth but must manufacture enough capital equipment to convert demand into reported sales. The competitive robotics backdrop remains active. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) recently received U.S. clearance and completed first cases with its next-generation ROSA Shoulder System. Intuitive Surgical, Inc. (ISRG - Free Report) is also expanding placements of its da Vinci 5 platform, reinforcing continued hospital interest in robotic-assisted surgery.
SYK Still Carries Cyber and Supply Risks
The recovery still carries costs. Cyber remediation and stabilization spending is expected to continue in the second half, while manufacturing and supply-chain pressures remain part of the margin picture. Those expenses can limit operating leverage even as production normalizes.
Peripheral Vascular is another execution point. A supply disruption created a meaningful U.S. back-order position and lost sales in the second quarter. Management expects those back orders to reach a manageable level by the end of the third quarter, but any slower improvement could affect the cadence of the broader recovery.
Stryker’s Ranking Signals Are Not Provided
The second-half setup is stronger, but it is not automatic. Backlog, capital demand and product activity support the growth case, while production constraints, vascular supply issues and cyber-related costs keep the risk-reward balance measured.
Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The near-term case rests on whether Stryker converts demand into sales while protecting the margin recovery. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.